Astellas Pharma (ALPMY) News Today → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free ALPMY Stock Alerts $9.48 -0.20 (-2.07%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14, 2024 | americanbankingnews.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Sees Large Growth in Short InterestMay 8, 2024 | prnewswire.comAstellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech CorridorMay 2, 2024 | msn.com7 Best Blue-Chip Dividend Stocks to BuyMay 1, 2024 | prnewswire.comAstellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in OncologyApril 26, 2024 | marketbeat.comShort Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Declines By 59.4%Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the target of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 69,800 shares, a decrease of 59.4% from the March 31st total of 171,800 shares. Based on an average daily volume of 701,300 shares, the days-to-cover ratio is presently 0.1 days.April 25, 2024 | msn.comAstellas Pharma Non-GAAP EPS of ¥84.19, revenue of ¥1603.67B; initiates FY24 guidanceApril 23, 2024 | markets.businessinsider.comEuropean Commission Approves Astellas' Xtandi For Recurrent Early Prostate Cancer TreatmentApril 23, 2024 | prnewswire.comAstellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment SettingApril 22, 2024 | markets.businessinsider.comTakeda, Astellas, Sumitomo Mitsui Banking To Form JV For Incubation Of Early Drug Discovery ProgramsApril 16, 2024 | marketbeat.comAstellas Pharma (OTCMKTS:ALPMY) Hits New 52-Week Low at $9.15Astellas Pharma (OTCMKTS:ALPMY) Hits New 1-Year Low at $9.15April 15, 2024 | finance.yahoo.comU.S. Stocks Erase Early GainsApril 15, 2024 | finance.yahoo.comStocks Lose Steam to Start Week; Goldman Rises After EarningsApril 15, 2024 | finance.yahoo.comStock Futures Up With Goldman Earnings in FocusApril 8, 2024 | marketbeat.comAstellas Pharma (OTCMKTS:ALPMY) Reaches New 12-Month Low at $10.28Astellas Pharma (OTCMKTS:ALPMY) Sets New 1-Year Low at $10.28April 4, 2024 | morningstar.comAstellas Pharma Inc ADRMarch 29, 2024 | msn.comChina NMPA accepts Astellas’ sBLA for urothelial cancer treatmentMarch 29, 2024 | marketbeat.comShort Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Grows By 51.6%Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the recipient of a large increase in short interest in March. As of March 15th, there was short interest totalling 112,200 shares, an increase of 51.6% from the February 29th total of 74,000 shares. Based on an average daily volume of 555,200 shares, the days-to-cover ratio is presently 0.2 days.March 28, 2024 | markets.businessinsider.comAstellas & Pfizer's SBLA For Enfortumab Vedotin With Keytruda Gets Approval In ChinaMarch 28, 2024 | finance.yahoo.comChina's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder CancerMarch 26, 2024 | finanznachrichten.deAstellas Pharma Inc.: Astellas' VYLOY (zolbetuximab) Approved in Japan for Treatment of Gastric CancerMarch 26, 2024 | finanznachrichten.deAstellas Pharma Receives Permanent J-code for IZERVAY (avacincaptad pegol intravitreal solution) for Geographic AtrophyMarch 26, 2024 | finance.yahoo.comAstellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric CancerMarch 26, 2024 | finance.yahoo.comAstellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic AtrophyMarch 22, 2024 | prnewswire.comAstellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment SettingMarch 20, 2024 | finance.yahoo.comQ4 2023 Taysha Gene Therapies Inc Earnings CallMarch 11, 2024 | finance.yahoo.comFDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in ChildrenMarch 11, 2024 | businesswire.comUbiquigent Enters Agreement With Astellas Subsidiary, Nanna TherapeuticsMarch 3, 2024 | prnewswire.comAstellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in JapanFebruary 27, 2024 | marketbeat.comAstellas Pharma (OTCMKTS:ALPMY) Share Price Crosses Below 50-Day Moving Average of $11.51Astellas Pharma (OTCMKTS:ALPMY) Share Price Passes Below 50-Day Moving Average of $11.51February 15, 2024 | finance.yahoo.comPADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) Granted Priority Review by Japan's Ministry of Health, Labour and Welfare for First-Line Treatment of Advanced Bladder CancerFebruary 15, 2024 | finance.yahoo.comAstellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology TherapeuticsFebruary 15, 2024 | prnewswire.comAstellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology TherapeuticsFebruary 7, 2024 | finance.yahoo.comAstellas Makes Announcement about Management StructureFebruary 1, 2024 | finance.yahoo.comAstellas to Air New VEOZAH® (fezolinetant) TV Spot During the Super BowlJanuary 31, 2024 | markets.businessinsider.comAstellas Submits SNDA In Japan For PADCEV-KEYTRUDA For Advanced Bladder Cancer TreatmentJanuary 31, 2024 | markets.businessinsider.comAstellas Pharma Announces Collaboration With Mass General BrighamJanuary 31, 2024 | finance.yahoo.comAstellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder CancerJanuary 30, 2024 | finance.yahoo.comAstellas Announces Strategic Collaboration with Mass General BrighamJanuary 30, 2024 | wsj.comAstellas Pharma Inc. ADRJanuary 26, 2024 | marketbeat.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Down 57.1% in JanuaryAstellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) saw a large drop in short interest during the month of January. As of January 15th, there was short interest totalling 68,200 shares, a drop of 57.1% from the December 31st total of 159,100 shares. Based on an average daily volume of 310,800 shares, the days-to-cover ratio is currently 0.2 days.January 23, 2024 | tmcnet.comVivtex Enters Research Collaboration with Astellas PharmaJanuary 11, 2024 | marketbeat.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Sees Large Increase in Short InterestAstellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 159,100 shares, a growth of 305.9% from the December 15th total of 39,200 shares. Based on an average daily volume of 554,500 shares, the days-to-cover ratio is currently 0.3 days.January 9, 2024 | finanznachrichten.deASTELLAS PHARMA INC.: Astellas Provides Update on Zolbetuximab Biologics License Application in U.S.January 9, 2024 | msn.comFDA denies approval of Astellas gastric cancer drugJanuary 8, 2024 | markets.businessinsider.comFDA Issues Complete Response Letter For Astellas' Zolbetuximab In HER2-Negative Gastric CancerJanuary 8, 2024 | finance.yahoo.comUS FDA declines to approve Astellas' gastric cancer drugJanuary 1, 2024 | marketbeat.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Down 14.6% in DecemberAstellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the recipient of a large decrease in short interest in the month of December. As of December 15th, there was short interest totalling 39,200 shares, a decrease of 14.6% from the November 30th total of 45,900 shares. Based on an average daily volume of 798,500 shares, the short-interest ratio is currently 0.0 days.December 31, 2023 | seekingalpha.comWeek In Review: $1.7B Collaboration Between Elpiscience And Astellas Is Final 2023 DealDecember 28, 2023 | markets.businessinsider.comElpiscience Biopharma, Astellas Pharma Collaborate For Novel Bi-specific Macrophage EngagersDecember 28, 2023 | msn.comAstellas and Elpiscience collaborate for novel bi-specific macrophage engagers Get Astellas Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter. Email Address [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. ALPMY Media Mentions By Week ALPMY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALPMY News Sentiment▼0.460.53▲Average Medical News Sentiment ALPMY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALPMY Articles This Week▼12▲ALPMY Articles Average Week Get Astellas Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALNY News Today TEVA News Today GMAB News Today BGNE News Today BMRN News Today VTRS News Today MKGAF News Today SRPT News Today UTHR News Today RDY News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:ALPMY) was last updated on 5/18/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceThe Presidential candidate you should REALLY be worried aboutStansberry ResearchProtect Your Bank Account Before It’s Too LateWeiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressWhat’s Really Next for America…Porter & CompanyHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astellas Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
